Financial Performance - Q2 FY27
- Total Income: ₹100.57 crore (₹1,005.7 million) compared to ₹79.58 crore in Q2 FY26, representing 26.4% YoY growth
- EBITDA: ₹36.32 crore compared to ₹24.97 crore in Q2 FY26
- EBITDA Margin: 36.7% compared to 31.7% in corresponding quarter
- PAT: ₹14.95 crore compared to ₹8.828 crore in Q2 FY26, representing 69% YoY growth
- PAT Margin: 15.1%
Operational Metrics - Q2 FY27
- Patients Served: 0.42 million
- Tests Performed: 2.4 million (corrected from 2.32 million mentioned in press release)
- Tests Per Patient: 5.7
- Revenue Per Patient: ₹2,348
- EBITDA Per Patient: ₹861
Financial Performance - H1 FY27
- Total Income: ₹189.31 crore (₹1,893.1 million) compared to ₹153.07 crore in H1 FY26, representing 23.7% YoY growth
- EBITDA: ₹67.85 crore compared to ₹49.62 crore in H1 FY26
- EBITDA Margin: 36.3%
- PAT: ₹27.796 crore compared to ₹18.00 crore in H1 FY26, representing 54% YoY growth
- PAT Margin: 14.9%
Operational Metrics - H1 FY27
- Patients Served: 0.8 million
- Tests Performed: 4.5 million
- Tests Per Patient: 5.63
- Revenue Per Patient: ₹2,335
- EBITDA Per Patient: ₹849
Network Expansion and Center Performance
- Total Centers: 77 centers at end of September 30, 2026
- New Centers Added in Q2: 5 centers, marking entry into Jharkhand
- Tripura Expansion: Infrastructure and equipment installation underway, operations expected to commence in second half of FY27
- Mature Centers (more than 2 years old): Delivered 42% EBITDA margin in Q2 FY27
- Centers under 2 years old: Improved to 11.8% EBITDA margin from negative 16.8% in corresponding period last year
- Centers more than 1 year old: Estimated margin around 30%
Geographical Revenue Mix - H1 FY27
- Greater Kolkata: 67% of revenues
- Rest of Bengal: 29% of revenues
- Other Regions: 4% of revenues
Business Segments and Initiatives
Genomics Division:
- Focus areas: Prenatal diagnostics, inherited diseases, pharmacogenomics, oncology-focused molecular panels
- Exploring advanced areas: Whole genome testing, metagenomics, AI integration
- Currently small vertical but considered promising for future growth
- East India described as "very underpenetrated market" for genomics
Strategic Collaborations:
- Asian Institute of Immunology and Rheumatology: Partnership for autoimmune diseases services
- Fetomat: Fetal medicine unit acquisition adding to prenatal diagnostics and genomic lab
Home Collection Services:
- Contributes approximately 10% of total revenues
- Expanding to newer geographies
B2B/Institutional Segment:
- Focus on holistic service platform to command marginally higher rates than competition
- Genomics expected to add to B2B business
Management Commentary and Guidance
Expansion Strategy:
- Target: 100 centers by end of FY28
- Post-FY28 expansion: 5-10 centers annually at slower pace
- Approach: Concentric expansion to minimize gestation period, cluster-based development
Margin Outlook:
- Steady-state margin for FY28 expected: 34-35%
- Mature centers expected to sustain around 42% margin
- Corporate costs include employee costs, marketing expense, and IT expense
Revenue Guidance:
- Committed to 15-18% annual growth
- Q3 FY27 expected to be muted due to festive season (Durga Puja, Diwali)
- Q4 typically stronger than Q3
Revenue Per Patient Outlook:
- Expected to hover around current levels (₹2,300-₹2,400)
- Growth drivers: Patient footfall increase rather than price hikes
- B2B business growth may limit revenue per patient increase
Cost Structure
- Depreciation and finance cost increase in Q2 FY27 due to new centers and lease agreements under IndAS 116
- Gross margin improved by 1% in quarter due to inventory consumption and reporting doctor fees
- Hub-and-spoke model used to maximize utilization of expensive equipment (MRI, CT scanners)
Competitive Positioning
- Integrated model (pathology, radiology, medical consultations) provides competitive advantage
- Focus on convenience and one-stop shop for patients
- Trust-based business with familiarity driving patient retention
Acquisition Strategy
- Evaluation parameters: Quality of asset, valuation, growth potential
- Preference for comprehensive diagnostics (radiology and pathology combined)
- Focus on assets that fill geographic gaps in current setup